PRIMARY STUDY

Targeting the endocannabinoid system for management of HIV-associated neuropathic pain: A systematic review

Key Findings:  The authors concluded that preclinical results suggest that targeting the ECS for prevention and treatment of HIV-NP is a plausible therapeutic option. Furthermore, clinical evidence shows that inhaled cannabis alleviates HIV-NP. More specifically, 2-AG and AEA, WIN 55,212-2, β-caryophyllene, AM1710, JWH015, JWH133; FAAH inhibitors (palmitoylallylamide, URB597 and PF-3845) prevented the development of and/or attenuated established HIV-NP.